Research Advance in the Risk Factors and Treatment of Sporadic Cerebral Amyloid Angiopathy

Abstract

Abstract:

Cerebral amyloid angiopathy (CAA) is a common intracranial microangiopathy among the aged people. The pathogenesis of CAA-related disorders, such as intracerebral hemorrhage, cognition impairment and so on, consists of two steps: cerebrovascular amyloid deposition and secondary vascular injury. The risk factors of CAA include ApoE gene polymorphisms and other genetic factors, as well as hypertension and other non-genetic factors. Immunotherapy and some natural polyphenols can prevent the cerebrovascular amyloid deposition, and the treatment of hypertension or the use of Edaravone can attenuate secondary vascular injury. These approaches are promising therapeutic targets for CAA.

Key words: Cerebral amyloid angiopathy; Risk factors; Immunotherapy; Natural polyphenols; Edaravone

摘要：

散发性脑淀粉样血管病（cerebral amyloid angiopathy，CAA）是一种老年人中常见的颅内微血管病。CAA相关病变（如脑出血、认知功能下降等）的发生主要包括淀粉样蛋白沉积于脑血管壁、继发血管损伤两个重要过程，其危险因素包括ApoE 基因多态性等遗传因素和高血压病等非遗传因素。免疫治疗和一些天然多酚类物质可防止脑血管内的淀粉样蛋白沉积，而控制高血压等非遗传危险因素或使用依达拉奉能减轻CAA继发血管损伤。这些方法有望成为今后散发性CAA治疗的发展方向。

关键词: 脑淀粉样血管病; 危险因素; 免疫治疗; 天然多酚; 依达拉奉

ZENG Fan, WANG Yan-Jiang. Research Advance in the Risk Factors and Treatment of Sporadic Cerebral Amyloid Angiopathy[J]. Chinese Journal of Stroke, 2015, 10(10): 878-882.

曾凡，王延江. 散发性脑淀粉样血管病的危险因素及治疗方法的研究进展[J]. 中国卒中杂志, 2015, 10(10): 878-882.

References

1 Charidimou A, Gang Q, Wer ring DJ. Sporadic

cerebral amyloid angiopathy revisited:recent insights

into pathophysiology and clinical spectrum[J]. J

Neurol Neurosurg Psychiatry, 2012, 83:124-137.

2 Yamada M. Cerebral amyloid angiopathy:emerging

concepts[J]. J Stroke, 2015, 17:17-30.

3 Love S, Miners S, Palmer J, et al. Insights into the

pathogenesis and pathogenicity of cerebral amyloid

angiopathy[J]. Front Biosci (Landmark Ed), 2009,

14:4778-4792.

4 Esiri MM, WilcockGK. Cerebral amyloid angiopathy

in dementia and old age[J]. J Neurol Neurosurg

Psychiatry, 1986, 49:1221-1226.

5 Carare RO, Bernardes-Silva M, Newman TA, et

al. Solutes, but not cells, drain from the brain

parenchyma along basement membranes of capillaries

and ar teries:signif icance for cerebral amyloid

angiopathy and neuroimmunology[J]. Neuropathol

Appl Neurobiol, 2008, 34:131-144.

6 Weller RO, Djuanda E, Yow HY, et al. Lymphatic

drainage of the brain and the pathophysiology of

neurological disease[J]. Acta Neuropathol, 2009,

117:1-14.

7 Sudlow C, Martínez González NA, Kim J, et al.

Does apolipoprotein E genotype influence the risk

of ischemic stroke, intracerebral hemorrhage, or

subarachnoid hemorrhage? Systematic review and

meta-analyses of 31 studies among 5961 cases and

17 965 controls[J]. Stroke, 2006, 37:364-370.

8 Brouwers HB, Bif f i A, McNamara KA, et al.

Apolipoprotein E genotype is associated with

CT angiography spot sign in lobar intracerebral

hemorrhage[J]. Stroke, 2012, 43:2120-2125.

9 O'Donnell HC, Rosand J, Knudsen KA, et al.

Apolipoprotein E genotype and the risk of recurrent

lobar intracerebral hemorrhage[J]. N Engl J Med,

2000, 342:240-245.

10 Leclercq PD, Murray LS, Smith C, et al. Cerebral

amyloid angiopathy in t raumatic brain injury:

association with apolipoprotein E genotype[J]. J Neurol

Neurosurg Psychiatry, 2005, 76:229-233.

11 Yamada M, Naiki H. Cerebral amyloid angiopathy[J].

Prog Mol Biol Transl Sci, 2012, 107:41-78.

12 Arima H, Tzourio C, Anderson C, et al. Effects

of perindopril-based lowering of blood pressure

on intracerebral hemorrhage related to amyloidangiopathy:the PROGRESS trial[J]. Stroke, 2010,

41:394-396.

13 Vonsattel JP, Myers RH, Hedly-Whyte ET, et al.

Cerebral amyloid angiopathy without and with

cerebral hemorrhages:a comparative histological

study[J]. Ann Neurol, 1991, 30:637-649.

14 Mc Car ron MO, Nicoll JA. Cerebral amyloid

angiopathy and thrombolysis-related intracerebral

haemorrhage[J]. Lancet Neurol, 2004, 3:484-492.

15 Vernooij MW, Haag MD, van der Lugt A, et al. Use

of antithrombotic drugs and the presence of cerebral

microbleeds:the Rotterdam Scan Study[J]. Arch

Neurol, 2009, 66:714-720.

16 Thoonsen H, Richard E, Bentham P, et al. Aspirin in

Alzheimer's disease:increased risk of intracerebral

hemorrhage:cause for concern?[J]. Stroke, 2010,

41:2690-2692.

17 王延江. 阿尔茨海默病的免疫治疗:进展、问题与展望

[J]. 中国医学前沿杂志, 2012, 4:13-16.

18 Schenk D, Barbour R, Dunn W, et al. Immunization

with amyloid-beta attenuates Alzheimer-diseaselike

pathology in the PDAPP mouse[J]. Nature, 1999,

400:173-177.

19 Holmes C, Boche D, Wilkinson D, et al. Long-term

effects of Abeta42 immunisation in Alzheimer's

disease:follow-up of a randomised, placebo-controlled

phase I trial[J]. Lancet, 2008, 372:216-223.

20 Boche D, Zotova E, Weller RO, et al. Consequence

of Abeta immunization on the vasculature of human

Alzheimer's disease brain[J]. Brain, 2008, 131:3299-

3310.

21 Thakker DR, Weatherspoon MR, Harrison J, et al.

Intracerebroventricular amyloid-beta antibodies

reduce cerebral amyloid angiopathy and associated

micro-hemorrhages in aged Tg2576 mice[J]. Proc Natl

Acad Sci USA, 2009, 106:4501-4506.

22 Prada CM, Garcia-Alloza M, Betensky RA, et

al. Antibody-mediated clearance of amyloid-beta

peptide from cerebral amyloid angiopathy revealed

by quantitative in vivo imaging[J]. J Neurosci, 2007,

27:1973-1980.

23 Li f sh i t z V, We i s s R , B en roma no T, e t a l .

Immunotherapy of cerebrovascular amyloidosis in a

transgenic mouse model[J]. Neurobiol Aging, 2012,

33:432.e1-432.e13.24 Ehrnhoefer DE, Bieschke J, Boeddrich A, et al.

EGCG redirects amyloidogenic polypeptides into

unstructured, off-pathway oligomers[J]. Nat Struct

Mol Biol, 2008, 15:558-566.

25 Rezai-Zadeh K, Shytle D, Sun N, et al. Green tea

epigallocatechin-3-gallate (EGCG) modulates

amyloid precursor protein cleavage and reduces

cerebral amyloidosis in Alzheimer transgenic mice[J].

J Neurosci, 2005, 25:8807-8814.

26 Lim GP, Chu T, Yang F, et al. The curry spice

curcumin reduces oxidative damage and amyloid

pathology in an Alzheimer transgenic mouse[J]. J

Neurosci, 2001, 21:8370-8377.

27 Hamaguchi T, Ono K, Murase A, et al. Phenolic

compounds prevent Alzheimer's pathology through

different effects on the amyloid-beta aggregation

pathway[J]. Am J Pathol, 2009, 175:2557-2265.

28 Liu KN, Lai CM, Lee YT, et al. Curcumin's preincubation

temperature affects its inhibitory potency

toward amyloid f ibrillation and f ibril-induced

cytotoxicity of lysozyme[J]. Biochim Biophys Acta,

2012, 1820:1774-1186.

29 Huang TC, LU KT, Wo YY, et al. Resverat rol

protects rats from Abeta-induced neurotoxicity

by the reduction of iNOS expression and lipid

peroxidation[J]. PLoS One, 2011, 6:e29102.

30 Ge JF, Qiao JP, Qi CC, et al. The binding of resveratrol

to monomer and fibril amyloid beta[J]. Neurochem Int,

2012, 61:1192-1201.

31 Feng Y, Wang XP, Yang SG, et al. Resveratrol inhibits

beta-amyloid oligomeric cytotoxicity but does not

prevent oligomer formation[J]. Neurotoxicology, 2009,

30:986-995.

32 Revesz T, Holton JL, Lashley T, et al. Genetics and

molecular pathogenesis of sporadic and hereditary

cerebral amyloid angiopathies[J]. Acta Neuropathol,

2009, 118:115-130.

33 Jiao SS, Yao XQ, Liu YH, et al. Edaravone alleviates

Alzheimer's disease-type pathologies and cognitive

deficits[J]. Proc Natl Acad Sci USA, 2015, 112:5225-

5230.

34 Mi l lucci L , Ghezzi L , Bermardini G, e t a l .

Conformations and biological activities of amyloid

beta peptide 25-35[J]. Curr Protein Pept Sci, 2010,

11:54-67.

[1]	. Effects of Post-stroke Infection on Discharge Outcomes in Patients with Acute Ischemic Stroke [J]. Chinese Journal of Stroke, 2023, 18(8): 885-890.
[2]	WANG Bei, TAN Bo, ZHANG Yue, LIU Yongdong, YANG Jiaqiang, ZOU Xueli, JIAO Yang, SUN Haijing. Risk Factors of Secondary Cerebral Infarction after Trepanation and Drainage in Patients with Hypertensive Intracerebral Hemorrhage [J]. Chinese Journal of Stroke, 2023, 18(05): 564-571.
[3]	ZHENG Xin, GUO Junping, ZHANG Runhua, JI Ruijun. Risk Factors of Lower Extremity Deep Vein Thrombosis in Patients with Acute Intracerebral Hemorrhage [J]. Chinese Journal of Stroke, 2023, 18(05): 577-582.
[4]	WU Juanjuan, NI Jun. Advances in the Mechanism of Cerebral Amyloid Angiopathy [J]. Chinese Journal of Stroke, 2021, 16(12): 1278-1283.
[5]	PAN Xin, GUO Na-Na, XUE Wei, LI Yi-Cai, LIU Jun-Ling, LI Xue-Mei. Prognosis and Recurrence of Ischemic Stroke under Stroke Management Model Guided by Stroke Health Manager [J]. Chinese Journal of Stroke, 2021, 16(04): 360-365.
[6]	SUN Yue, CHEN Yi-Tong, LI Xing, ZHANG Run-Hua. Analysis of Risk Factors for Ischemic Stroke-associated Pneumonia [J]. Chinese Journal of Stroke, 2021, 16(04): 366-370.
[7]	LU Zheng-Qi, LI Tie-Mei. Progress in Treatment of Age-related Cerebral Small Vessel Diseases [J]. Chinese Journal of Stroke, 2020, 15(04): 371-375.
[8]	Mirezhati TUERHONG, Aximujiang AXIER, Kaheerman KADEER, CHENG Xiao-Jiang, LI Xue-Liang, Nizamidingjiang REXIATI, Yadikaer AIHEMAITI,Maimaitiaili NUERDONG, Yaermaimaiti ATAWULA. Relationship between Carotid Tortuosity and Anterior Circulation Aneurysms [J]. Chinese Journal of Stroke, 2020, 15(03): 269-274.
[9]	LI Meng, LI Guo-Zhong, ZHONG Di. Progress in Research on Cortical Superficial Siderosis [J]. Chinese Journal of Stroke, 2020, 15(03): 320-325.
[10]	XU Mo-Ju, LI Zhan-Yong. Progress of the Effect of Edaravone on Cognitive Impairment [J]. Chinese Journal of Stroke, 2020, 15(03): 326-331.
[11]	LU Zheng-Qi, SONG Kang-Yu. Pathological Basis and Imaging Characteristics of Spectrum of Age-related Cerebral Small Vessel Diseases [J]. Chinese Journal of Stroke, 2019, 14(11): 1119-1123.
[12]	YU Yang, HAO Chun-Yan, WANG Lu, YANG Li-Jun, LI Fang, LI Bo, LIU Jie, LIU Ju-Wei, MA Jin-Kui. Evaluation of Stroke Risk Profile and Its Correlation with Related Risk Factors in Middle-aged and Eldly Male Population [J]. Chinese Journal of Stroke, 2019, 14(03): 213-218.
[13]	JIANG Li-Min, YANG Jia-Lei, LI Xiao-Gang. Correlation between Normal Homocysteine Levels and Recurrent Cerebral Infarction [J]. Chinese Journal of Stroke, 2018, 13(10): 1035-1038.
[14]	LU Yu-Qiao, KONG Jun-Hui, ZHANG Zhi-Chen, ZHANG Ye, ZHANG Wei-Dong, LIU Xue-Mei. Analysis of Dyslipidemia and Its Risk Factors in Community Population with High-risk of Stroke at Fengtai District of Beijing [J]. Chinese Journal of Stroke, 2018, 13(10): 1039-1043.
[15]	LI Shu-Ya, ZHAO Xing-Quan, LIU Li-Ping, WANG Chun-Xue, LIU Gai-Fen, WANG Yi-Long, WANG Yong-Jun. Validity Comparison of Three Scores Tool for 1-year Death Risk Assessment in Chinese Ischemic Stroke Patients with Atrial Fibrillation [J]. Chinese Journal of Stroke, 2018, 13(08): 818-822.